Janssen and Capricor reach licensing deal for cell therapy program

jack1381818

Janssen Inks Up to $337.5M Cell Therapy Collaboration with Capricor
8 s: \6 Q. E& D- @# M0 `- O
* f' ?' H; m, y7 [- G. ]3 V* zJohnson & Johnson’s Janssen Biotech entered into an exclusive license option agreement to develop Capricor Therapeutics’ cell therapy program for cardiovascular applications—including its lead product, CAP-1002, a heart-disease treatment now heading into Phase II clinical trials—in a deal that could net Capricor as much as $337.5 million.: ?' e, t) ~! q
/ y/ _0 E/ a/ N* M+ L; Q: N/ X
Janssen agreed to pay Capricor $12.5 million up front, and up to $325 million if Janssen exercises option rights, plus royalties on commercial sales of CAP-1002. Under the agreement, Janssen has the right to enter into an exclusive license agreement for CAP-1002 at any time until 60 days after Capricor delivers six-month follow-up results from Phase II of its ALLSTAR clinical trial for the cell therapy.! G: b+ v# {( w7 [

* L0 C" Q6 U( k- E3 I/ dCAP-1002 is an allogeneic cardiosphere-derived cell therapy under study in patients who have suffered a large myocardial infarction.
/ X, T2 o+ I7 }/ e- ~- R7 C  w+ T) }6 j$ E  G7 F
"This collaboration with Janssen, one of the world's largest and most respected healthcare companies with a strong presence in cardiovascular and metabolism, is a tremendous milestone for Capricor Therapeutics and an important validation of our lead product, CAP-1002, and the underlying science,” Capricor CEO Linda Marban, Ph.D., said in a statement.! ~1 M- T3 Y. c! O" j4 I$ G5 j
" R% g; B0 q1 Z& ~' ?1 I# h9 e# f
Capricor has won about $19.8 million in funding from California’s stem-cell agency, the California Institute for Regenerative Medicine (CIRM), toward the Phase II trial, through CIRM’s Disease Team Therapy Development-Research program. The trial will be designed to assess both safety and efficacy of a heart-derived stem cell product in patients who have experienced a heart attack either recently or in the past.
2 s5 c- c& P' P) [: U
( A: W8 i' r# _* R* SCapricor told CIRM its Phase I data suggest that treatment with the heart-derived cell product under development can turn scar tissue back into healthy heart muscle. The clinical program for CAP-1002 also builds upon earlier research for which Eduardo Marbán, M.D., Ph.D., director of the Cedars-Sinai Heart Institute, won an earlier $5.56 million Disease Team Research I grant from CIRM.
- e; I( R# L2 u3 o1 }! U4 w4 J0 S6 O& Y" z7 N! S3 o
“The planned mid-stage trial will hopefully confirm that finding in a larger patient group and provide additional data to support the safety profile of the product,” the company stated in an abstract of the research published on CIRM’s website.) q, m$ W' B! s# @* `" @

0 X7 e) c( ?1 p, P0 aA successful Phase II trial would be followed by a Phase III study, then a marketing application to the FDA, Capricor added: “The end result could be an affordable stem cell therapy effective as part of a treatment regimen after a heart attack.”1 Z7 _* B$ p/ v, ^& L  Q: _

4 P# p# G2 ?, a% U) Z' `5 lCapricor became publicly traded in July following its merger with Nile Therapeutics, under which Capricor became a wholly owned subsidiary of Nile.
4 z7 L1 I8 S4 N9 X( O$ P5 h8 U3 z4 e. a4 j, c( M7 P